» Articles » PMID: 15542682

Effects of Mutations in the G Tract of the Human Immunodeficiency Virus Type 1 Polypurine Tract on Virus Replication and RNase H Cleavage

Overview
Journal J Virol
Date 2004 Nov 16
PMID 15542682
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

The RNase H cleavages that generate and remove the polypurine tract (PPT) primer during retroviral reverse transcription must be specific in order to create a linear viral DNA that is suitable for integration. Lentiviruses contain a highly conserved sequence consisting of six guanine residues at the 3' end of the PPT (hereafter referred to as the G tract). We introduced mutations into the G tract of a human immunodeficiency virus type 1-based vector and determined the effects on the virus titer and RNase H cleavage specificity. Most mutations in the G tract had little or no effect on the virus titer. Mutations at the second and fifth positions of the G tract increased the proportion of two-long-terminal-repeat (2-LTR) circle junctions with one or two nucleotide insertions. The second and fifth positions of the G tract make specific contacts with amino acids in the RNase H domain that are important for RNase H cleavage specificity. These complementary data define protein-nucleic acid interactions that help control the specificity of RNase H cleavage. When the G-tract mutants were analyzed in a viral background that was deficient in integrase, in most cases the proportion of consensus 2-LTR circle junctions increased. However, in the case of a mutant with Ts at the second and fifth positions of the G tract, the proportion of 2-LTR circle junctions containing the one-nucleotide insertion increased, suggesting that linear viral DNAs containing an extra base are substrates for integration. This result is consistent with the idea that the 3' end-processing reactions of retroviral integrases may help to generate defined ends from a heterogenous population of linear viral DNAs.

Citing Articles

HIV Replication Under High-Level Cabotegravir Is Associated with the Appearance of 3'-PPT Mutations, Circular DNA Transcription and Recombination.

Wei X, Lipscomb J, Tino A, Cong M, Ruone S, Bentz M Viruses. 2025; 16(12.

PMID: 39772184 PMC: 11680205. DOI: 10.3390/v16121874.


HIV ribonuclease H: continuing the search for small molecule antagonists.

Wendeler M, Beilhartz G, Beutler J, Gotte M, Le Grice S HIV Ther. 2024; 3(1):39-53.

PMID: 38961883 PMC: 11221599. DOI: 10.2217/17584310.3.1.39.


HIV-1 3'-Polypurine Tract Mutations Confer Dolutegravir Resistance by Switching to an Integration-Independent Replication Mechanism via 1-LTR Circles.

Dekker J, Klaver B, Berkhout B, Das A J Virol. 2023; 97(5):e0036123.

PMID: 37125907 PMC: 10231180. DOI: 10.1128/jvi.00361-23.


Identification of an integrase-independent pathway of retrotransposition.

Li F, Lee M, Esnault C, Wendover K, Guo Y, Atkins P Sci Adv. 2022; 8(26):eabm9390.

PMID: 35767609 PMC: 11042837. DOI: 10.1126/sciadv.abm9390.


Specific mutations in the HIV-1 G-tract of the 3'-polypurine tract cause resistance to integrase strand transfer inhibitors.

Hachiya A, Kubota M, Shigemi U, Ode H, Yokomaku Y, Kirby K J Antimicrob Chemother. 2021; 77(3):574-577.

PMID: 34894227 PMC: 8865006. DOI: 10.1093/jac/dkab448.


References
1.
Rattray A, Champoux J . Plus-strand priming by Moloney murine leukemia virus. The sequence features important for cleavage by RNase H. J Mol Biol. 1989; 208(3):445-56. DOI: 10.1016/0022-2836(89)90508-1. View

2.
Bushman F, Craigie R . Activities of human immunodeficiency virus (HIV) integration protein in vitro: specific cleavage and integration of HIV DNA. Proc Natl Acad Sci U S A. 1991; 88(4):1339-43. PMC: 51013. DOI: 10.1073/pnas.88.4.1339. View

3.
Li L, Olvera J, Yoder K, Mitchell R, Butler S, Lieber M . Role of the non-homologous DNA end joining pathway in the early steps of retroviral infection. EMBO J. 2001; 20(12):3272-81. PMC: 150207. DOI: 10.1093/emboj/20.12.3272. View

4.
Julias J, Ferris A, Boyer P, Hughes S . Replication of phenotypically mixed human immunodeficiency virus type 1 virions containing catalytically active and catalytically inactive reverse transcriptase. J Virol. 2001; 75(14):6537-46. PMC: 114377. DOI: 10.1128/JVI.75.14.6537-6546.2001. View

5.
Rausch J, Lener D, Miller J, Julias J, Hughes S, Le Grice S . Altering the RNase H primer grip of human immunodeficiency virus reverse transcriptase modifies cleavage specificity. Biochemistry. 2002; 41(15):4856-65. DOI: 10.1021/bi015970t. View